F8 and hemophilia: (22) separately demonstrated that pretreatment with a single dose of 1-mg human-derived C1 domain IgG1 MAb KM33 followed by 3 weeks of 1-μg FVIII injections (1,000-fold MAb-to-FVIII ratio) abolished antibody development in exon 17 knockout hemophilia A mice.